Rapid, accurate and highly customizable assay platforms for pharmacogenomic studies
The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number targets and the sensitivity requirements are highly diverse in different studies. Here we describe the design, performance and regulatory considerations of several assay platforms that are accurate, high throughput, cost effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.
What will you learn?
- State-of-the-art pharmacogenomic assay platforms currently available
- How to select the optimal platform and assay design to meet the needs of individual studies
- Performances of several commercial or customized pharmacogenomic tests
- Regulatory considerations for pharmacogenomic studies
Who may this interest?
- Researchers in genetic diseases, drug metabolism and related areas
- Drug developers performing R&D and clinical trials
- Clinicians who treat genetic disorders or provide personalize precision medicine
- Genomic service providers who provide or support pharmacogenomic testing
Speaker
Dr Peter Zhang
SME
Frontage Laboratories (PA, USA).
Dr Peter Zhang is a subject matter expert at Frontage Laboratories (PA, USA). He received his PhD in 2003 and spent 12 years in academia as Professor of Functional Genomics. He has authored or coauthored over 50 peer-reviewed journal articles and book chapters. Dr Zhang has taken on various technical leadership roles in the industry in the past 5 years. He currently supports genomic services at Frontage, including all PCR- and NGS-based assay platforms.
In association with
